Medpace Holdings Inc vs Nebius Group NV — how do they compare? Medpace Holdings Inc trades at $530.31 (market cap $15.08B), while Nebius Group NV trades at $207.2 (market cap $46.37B). The key difference: Nebius Group NV is far larger — about 3.1× Medpace Holdings Inc's market cap. Which is the better fit depends on your goals.
| MEDP | NBIS | |
|---|---|---|
Market Cap | $15.08B | $46.37B |
Sector | Technology | Technology |
52-Week High | $620.59 | $286.69 |
52-Week Low | $308.88 | $50.40 |
Enterprise Value | $14.55B | $46.56B |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
NBIS trades at $182.62, up 2.76% today, with a bullish technical signal despite recent volatility. The company reported Q1 2026 EPS of -$0.23, beating expectations, and secured a $775 million debt facility to accelerate AI cloud expansion. Analyst consensus remains strongly positive with an $242 price target, though high valuation ratios (P/E 68.61, P/S 53.73) reflect growth expectations.
Outlook is supported by robust AI demand and a debt-free balance sheet, but risks include intense competition and execution challenges in scaling infrastructure. The stock offers significant upside if growth targets are met, yet remains sensitive to sector sentiment shifts and capital expenditure pressures.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →